Rising Government Support for Vaccines could Aid Development of Influenza Medication Market, says TMR

Transparency Market Research (TMR) announces a new report on the global influenza medication market. The report examines the present figures and past historical trajectory of the influenza medication market in order to present a thorough overview of the market and reliable predictions regarding its development in the coming years. The report is titled ‘Influenza Medication Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025.’

Influenza, caused by the influenza virus, is not a deadly disease in itself, but can lead to more severe complications such as pneumonia. This has driven the global influenza medication market, as preventive medicine rather than curative treatments have become preferred in the healthcare sector of late. Influenza is an infectious respiratory disease and peaks in winter, when the conditions allow for rapid growth of the influenza virus. The global influenza medication market is driven by the rising number of hospitalizations due to influenza-related complications. More than 200,000 hospitalizations occur every year due to influenza in the U.S. alone, making growth of the influenza medication market certain in the coming years.

Based on type of medication, the global influenza medication market is segmented into light influenza medication (antibiotics), typical influenza medication (antivirals), and pneumonia influenza medication. Typical influenza medications are likely to remain the leading revenue generator in the global influenza medication market due to their effectiveness in eradicating influenza. Zanamivir, peramivir, and oseltamivir are the key types of typical influenza medication. The effectiveness of antivirals in eradicating influenza is likely to lead to them holding a dominant share in the global influenza medication market in the coming years. However, light influenza medication is also becoming popular among patients due to the ease of self-administering mild antibiotics.

Growing government participation in the widespread adoption of influenza medication, particularly influenza vaccines, is likely to remain a key driver for the global influenza medication market in the coming years. Annual vaccines remain the most effective way of preventing influenza outbreaks, but the high cost of vaccines has held back this avenue in several developing markets. Government support is thus likely to be crucial for the global influenza medication market in the coming years.

By distribution channel, the global influenza medication market is dominated by hospitals, followed by pharmacies, clinics, and others. Pharmacies are likely to become a key player in the global influenza medication market due to the rising availability of OTC influenza medication. The growing support from the FDA to OTC influenza medication is likely to drive the demand for influenza medication from pharmacies in the coming years.

Geographically, the Asia Pacific influenza medication market is likely to exhibit rapid growth in the coming years due to the rising disposable income of patients in the region and the growing healthcare infrastructure, which has led to easier availability of influenza medication.

The report also assesses the key players operating in the global influenza medication market in order to shed light on the competitive dynamics of the market. Leading companies profiled in the report include AstraZeneca, Eli Lilly and Company, F. Hoffman-La Roche Ltd., Bristol-Myers Squibb, Bayer AG, Novartis AG, GlaxoSmithKline Plc, Sanofi, Pfizer Inc., and Celgene Corporation.

Request to view Sample Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=24038